RALGAPA1

Across TCGA pan-cancer cohorts, RALGAPA1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RALGAPA1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RALGAPA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RALGAPA1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, LSCC, and CCRCC are the cancer types where RALGAPA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.855	0.650	<.001	14	view →
LSCC	DFS	Quartile	II,III,IV	0.956	0.650	.009	11	view →
CCRCC	DFS	Median	III,IV	0.960	0.769	.016	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RALGAPA1–GBM (DFS)

Open the GBM breakdown →